Touting positive Ph II data, Probiodrug doubles down on amyloid approach to Alzheimer's

While researchers have long tangled over the pathology of Alzheimer’s disease (AD), recent trial failures have renewed interest in tau proteins as a therapeutic target.

Others maintain that the weight of scientific evidence is too great for the ‘amyloid hypothesis’ to be ignored altogether.

Konrad Glund, chief executive of German AD firm Probiodrug (AMS: PBD) argues that, with solanezumab, Eli Lilly (NYSE: LLY) made the mistake of: “targeting soluble Abeta,” whereas “the toxic culprit is really the early oligomers.”